UPDATE: Goldman Sachs Lowers PT on Infinity Pharmaceuticals on Multiple Negative Factors
July 05, 2013 at 09:29 AM EDT
In a report published Friday, Goldman Sachs analyst Navdeep Singh reiterated a Neutral rating on Infinity Pharmaceuticals (NASDAQ: INFI ), but lowered the price target from $40.00 to $20.00. In the report, Goldman Sachs noted, “We are lowering our 12-month price target for INFI to $20 (from $40) due to
